Esperion Therapeutics - Ann Arbor Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Esperion Therapeutics - Ann Arbor's estimated annual revenue is currently $93.3M per year.
- Esperion Therapeutics - Ann Arbor received $151.9M in venture funding in August 2017.
- Esperion Therapeutics - Ann Arbor's estimated revenue per employee is $201,000
- Esperion Therapeutics - Ann Arbor's total funding is $22.8M.
- Esperion Therapeutics - Ann Arbor has 464 Employees.
- Esperion Therapeutics - Ann Arbor grew their employee count by 229% last year.
- Esperion Therapeutics - Ann Arbor currently has 10 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Frank W. Kerr C...||$6.4M||32||N/A||N/A||N/A|
|Ash Stevens, a ...||$27.7M||138||-1%||N/A||N/A|
|Gage Cannabis U...||$15.1M||75||134%||N/A||N/A|
What Is Esperion Therapeutics - Ann Arbor?
Esperion is the Lipid Management Company passionately committed to developing and commercializing convenient, complementary, consistent, once-daily, oral therapies for the treatment of patients with elevated LDL-C. Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering therapies that will make a substantial impact on reducing global cardiovascular disease; the leading cause of death around the world. The Company has two late-stage therapies in development; both with confirmed regulatory pathways to approval and defined global pivotal Phase 3 clinical development plans. Bempedoic acid and the Company's lead product candidate, the bempedoic acid / ezetimibe combination pill, are targeted therapies that have been shown to significantly reduce elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. Phase 1 and 2 studies conducted previously in more than 800 patients treated with bempedoic acid have produced clinically relevant LDL-C lowering results of up to 30 percent as monotherapy, approximately 50 percent in combination with ezetimibe, 64% when added-on to atorvastatin 20 mg, and an incremental 20+ percent when added to stable statin therapy. The Company has two Phase 3 products in development: 1) the once-daily, oral fixed dose bempedoic acid / ezetimibe combination pill, and 2) bempedoic acid (monotherapy) a once-daily, oral pill. For more information, please visit www.esperion.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Regina Gore Cavaliere||Chief Ethics and Compliance Officer||Email Available|
|Tim Mayleben||CEO/President||Email Available|
|Marianne Andreach||Senior Vice President, Product Planning||Email Available|
|Pragna Patel||Director Clinical Operations||Email Available|
|Jo Wells||Director, Clinical Quality Assurance||Email Available|
|Eric Jozefiak||Senior Director||Email Available|
|Jeanne Brittain||Associate Director of Project||Email Available|
|Heather Persh||Associate Director, Human Resources||Email Available|
|Matt Bigert||Senior Director - Analytical Research and Development||Email Available|
|Kimberly Stranick||Vice President|
Esperion Therapeutics - Ann Arbor News
ANN ARBOR—Esperion Therapeutics Inc., a developer of a new class of cholesterol-reducing drugs, announced that the compensation ...
ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment ...
ANN ARBOR, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development ...
Esperion Therapeutics - Ann Arbor Funding
|2015-03-19||$172.5M||Undisclosed||Credit Suisse Securities (USA)||Article|
Esperion Therapeutics - Ann Arbor Executive Hires
|2002-07-17||William Brinkerhoff||VP Business Development||Article|
|2003-06-06||Adeoye Olukotun||SVP Clinical/Reg Aff/CMO||Article|
|2012-04-10||Noah Rosenberg||Chief Medical Officer||Article|
|2014-01-14||Antonio M. Gotto||Director||Article|
Esperion Therapeutics - Ann Arbor Acquisitions